SCHEMBL2237141

SCHEMBL2237141

Cc1ccc(OS(=O)(=O)c2ccc(N3CCCNC3=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ENPP3 O14638 2/20 0.43
ENPP1 P22413 2/20 0.43
ENPP2 Q13822 2/20 0.43
THRB P10828 1/20 0.40
MGAM O43451 1/20 0.40
CYP1A1 P04798 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235106 0.94 LMNA (0.56) SMN1; SMN2LMNAGAAALDH1A1MEN1
SCHEMBL2303056 0.94 LMNA (0.56) SMN1; SMN2LMNAGAAALDH1A1MEN1
SCHEMBL2240051 0.88 TDP1 (0.48) SMN1; SMN2LMNAGAAALDH1A1MEN1
SCHEMBL2239957 0.88 ENPP3 (0.43) SMN1; SMN2LMNAGAAALDH1A1MEN1
SCHEMBL2239453 0.86 ALDH1A1 (0.48) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL2233885 0.83 ALDH1A1 (0.39) SMN1; SMN2LMNAGAAALDH1A1HTT
SCHEMBL2302983 0.83 GAA (0.61) SMN1; SMN2LMNAGAAHTTPKM
SCHEMBL2234141 0.83 GAA (0.61) SMN1; SMN2LMNAGAAHTTPKM
SCHEMBL8286230 0.82 SMN1; SMN2 (0.54) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL14217339 0.82 SMN1; SMN2 (0.61) SMN1; SMN2LMNAGAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 SMN1; SMN2 2479/4885LMNA 2765/4885GAA 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.